Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines

Jinturkar, Kaustubh A.; Anish, Chakkumkal; Kumar, Mukesh; Bagchi, Tamishraha; Panda, Amulya K.; Misra, Ambikanandan

doi:10.1016/j.biomaterials.2011.11.067

Cited by 60 publications

(42 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNAse enzyme is responsible for degradation of pDNA and is the major obstacle for pDNA transfection in the cells. Our results are in concordance with previous reports which proved that complexation of pDNA with polymeric or lipidic delivery system protect pDNA from DNAse enzyme and enhance its stability in biological milieu (Jinturkar et al, 2012;Al-Deen et al, 2013). The polymethacrylate vectors could protect pDNA from DNAse enzyme very effectively which will improve in vivo transfection.…”

Section: Dnase I Sensitivity Testsupporting

confidence: 92%

Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer

Bhatt¹,

Khatri²,

Kumar³

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

This study was aimed to develop and evaluate p53 polyplex-loaded enteric-coated calcium pectinate microbeads for oral gene delivery as an effective novel alternative for colorectal cancer therapy. Mutation in p53 is the key event in colorectal cancer (CRC) and an important target for the treatment of CRC through gene therapy. Polymethacrylates-based non-viral vectors were evaluated for their ability to complex, protect and transfect p53 (wt) into colon cancer cell line. Polyplexes were formulated by complexation of cationic polymer with anionic pDNA at different N/P ratios. p53 polyplex-loaded calcium pectinate (CP) microbeads were prepared by ionotropic gelation of pectin with calcium chloride and coated with Eudragit Õ S100. In vitro release studies showed that enteric-coated CP microbeads protected the release of p53 polyplex in upper GIT with less than 10% release. In-vitro cell line studies and in vivo studies in rat showed that polymethacrylate carrier could transfect the pDNA effectively. Results of in vivo gene expression study further confirmed the ability of enteric-coated calcium pectinate microbeads to deliver pDNA specifically to rat colon. Conclusively, enteric-coated calcium pectinate microbeads released p53 polyplex specifically in colon and could serve as an effective alternative for CRC therapy.

show abstract

Section: Dnase I Sensitivity Testsupporting

confidence: 92%

Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer

Bhatt¹,

Khatri²,

Kumar³

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…etoposide and docetaxel, and plasmid DNA encoding the tumor suppressor gene p53 for a triple action chemotherapy to be delivered by dry powder inhalation. The powder was obtained by freeze-drying using trehalose as cryoprotectant (Jinturkar et al, 2012). This method of delivery of the drugs and the p53 gene was developed to reduce the incidence of tumor p53 inactivation mediated drug resistance, which is a common cause for treatment failure in all types of chemotherapy, by supplementing the endogenous p53 genes and inducing p53-mediated apoptosis (Lowe et al, 1994).…”

Section: Dry Powder Inhalersmentioning

confidence: 99%

“…Lung cancer is characterized by uncontrolled cellular growth in the tissue of the lung that may metastasize and spread into other tissue in the lung or elsewhere in the body (Jinturkar et al, 2012). Of the known types of lung cancer, there are two main forms -small cell lung carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC), of these, the majority of lung cancers fall into the latter category ($80%) with a significant proportion of the remainder falling into the category of SCLC (Celikoglu et al, 2008;Jinturkar et al, 2012). Despite significant research and developments in the detection and treatment of NSCLC, the majority of tumors are not detected until the cancer is at an advanced stage, meaning the prognosis is poor and treatment options are limited.…”

Section: Introductionmentioning

confidence: 99%

“…Despite significant research and developments in the detection and treatment of NSCLC, the majority of tumors are not detected until the cancer is at an advanced stage, meaning the prognosis is poor and treatment options are limited. SCLC sufferers have a very poor prognosis with less than 10% survival rates at 5 years (Jinturkar et al, 2012;Zarogoulidis et al, 2012a). The preferred treatment option is surgical resection of the cancerous tissue; however, being difficult to ensure that all of the cancerous tissue is removed, resection is supplemented with radiotherapy or chemotherapy (Kang et al, 2011;Jinturkar et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

“…These treatments in many cases display limited efficacy due to poor selectivity, dose-limiting levels of systemic toxicity (including anemia, nausea, vomiting, neurotoxicity, and nephrotoxicity), and the development of multidrug resistance such as that seen with P-glycoprotein and multi-drug-resistant pumps (Tseng et al, 2009;Jinturkar et al, 2012;Videira et al, 2012). Furthermore, many of the most effective treatments for lung cancer such as paclitaxel, docetaxel, doxorubicin, camptothecins, and quercetin are highly lipophilic molecules with very poor aqueous solubility (El-Gendy & Berkland, 2009;Willis et al, 2012;Verma et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Loco-regional administration of nanomedicines for the treatment of lung cancer

et al. 2015

View full text Add to dashboard Cite

Lung cancer poses one of the most significant challenges to modern medicine, killing thousands every year. Current therapy involves surgical resection supplemented with chemotherapy and radiotherapy due to high rates of relapse. Shortcomings of currently available chemotherapy protocols include unacceptably high levels of systemic toxicity and low accumulation of drug at the tumor site. Loco-regional delivery of nanocarriers loaded with anticancer agents has the potential to significantly increase efficacy, while minimizing systemic toxicity to anticancer agents. Local drug administration at the tumor site using nanoparticulate drug delivery systems can reduce systemic toxicities observed with intravenously administered anticancer drugs. In addition, this approach presents an opportunity for sustained delivery of anticancer drug over an extended period of time. Herein, the progress in the development of locally administered nanomedicines for the treatment of lung cancer is reviewed. Administration by inhalation, intratumoral injection and means of direct in situ application are discussed, the benefits and drawbacks of each modality are explored.

show abstract

Reduction‐Sensitive Polymeric Micelles Based on Docetaxel‐Polymer Conjugates Via Disulfide Linker for Efficient Cancer Therapy

Guo

Zhang

Zhao

et al. 2015

Macromolecular Bioscience

View full text Add to dashboard Cite

In this article, the low-molecular weight biodegradable methoxy poly (ethylene glycol)-poly (D,L-lactide-co-glycolide) (PP) is chosen as polymeric skeleton to be conjugated with docetaxel (DTX) by disulfide bond (PP-SS-DTX) to construct the reduction-sensitive drug delivery system. The conjugates are synthesized via three steps and are further employed to physically load free DTX to develop the PP-SS-DTX/DTX micelles which exhibit many merits including high drug loading content, good stability, and stimuli-sensitive release of drugs. The hydrodynamic diameter of PP-SS-DTX/DTX micelles determined by DLS is 112.3 nm. The hemolysis assay reveals the good blood compatibility of PP-SS-DTX/DTX micelles. In order to investigate the reductive sensitivity of PP-SS-DTX/DTX micelles, dithiothreitol (DTT) is added into the release medium and a programmed drug release mode is observed in the conjugated micelles. In vitro cytotoxity assay shows that the PP-SS-DTX/DTX micelles are more cytotoxic than that of free DTX solution for both MCF-7 and B16F10 cancer cells. In addition, the PP-SS-DTX/DTX micelles also show a higher cellular uptake rate than that of free DTX. Hence, the prepared reduction-sensitive PP-SS-DTX/DTX micelles are effective on inhibiting cancer cells compared with the free DTX which would be a promising carrier in cancer therapy.

show abstract

Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines

Cited by 60 publications

References 30 publications

Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer

Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer

Loco-regional administration of nanomedicines for the treatment of lung cancer

Reduction‐Sensitive Polymeric Micelles Based on Docetaxel‐Polymer Conjugates Via Disulfide Linker for Efficient Cancer Therapy

Contact Info

Product

Resources

About